CLINICAL STUDIES OF CEFROXADINE (CGP-9000) IN THE FIELD OF OBSTETRICS AND GYNECOLOGY

• Published in: CHEMOTHERAPY Vol. 28; no. Supplement3; pp. 540 - 549
• Main Authors: CHO, NANKUN, ISHIDA, TAMAMI, SEO, FUMIHIRO, TAKENOUCHI, TAMIO, OZAKI, TOSHIO, SEKI, MASANORI, SANAI, YASUHIRO, NAKAYAMA, TETSUYA, KUNII, KATSUAKI, FUKUNAGA, KANGO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 01.01.1980
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.28.Supplement3_540

Laboratory and clinical studies were done on Cefroxadine (CGP-9000, CXD), a new orally active of cephalosporin, in the field of obstetrics and gynecology and the following results were obtained. 1) Antimicrobial activities presented in terms of MICs were as follows: 1.56μg/ml against S. epidermidis 0.39-1.56μg/ml against S. aureus, 0.78-12.5μg/ml against S. faecalis, 6.25-12.5μg/ml against E. coli and 12.5μg/ml against P. mirabilis. 2) CXD was absorbed rapidly and transfered well into umbilical cord blood and amniotic fluid. 3) CXD was administered orally with daily dose of 0.75-1.0 g to 30 cases of urinary tract infections and 13 cases of infections of genital organs. The clinical response was good and efficacy rate was about 96%.No noteworthy side effects were noted with the drug.